A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
To evaluate the efficacy and safety of apatinib combined with adebrelizumab and EC in the first-line treatment of extensive small cell lung cancer
Small Cell Lung Cancer Extensive Stage
DRUG: Apatinib|DRUG: Adebrelimab|DRUG: Etoposide Injection|DRUG: Carboplatin Injection
Progression free survival, Defined as the time from the start of enrollment to the date when objective tumor progression was first recorded or to death from any cause, whichever occurs first., 0ne year
Objective remission rate, Proportion of subjects with CR and PR (RECIST v1.1 standard), one year|Disease control rate, Proportion of subjects with CR and PR and SD (RECIST v1.1 standard), one year|Overall survival, Defined as the time between enrollment and the subject's death from various causes;, 2 years|Safety and tolerance evaluated by incidence, severity and outcomes of AEs, Safety and tolerance will be evaluated by incidence, severity and outcomes of AEs and categorized by severity in accordance with the NCI CTC AE Version 5.0, 2 years
To evaluate the efficacy and safety of apatinib combined with adebrelizumab and EC in the first-line treatment of extensive small cell lung cancer